Skip to main content
Premium Trial:

Request an Annual Quote

Myriad to Replace BRACAnalysis, Other Hereditary Cancer Tests with MyRisk Panel

NEW YORK (GenomeWeb News) – Myriad Genetics said during its analyst and investor day today that it will launch a new multi-hereditary cancer panel, called myRisk Hereditary Cancer, by the end of this year that will replace its existing BRACAnalysis and other hereditary cancer tests by the summer of 2015.

The new panel will initially focus on breast, colon, ovarian, endometrial, and pancreatic cancer, as well as melanoma, and will expand to lung, prostate, and other cancers in the future, Mark Capone, president of Myriad Genetics Laboratories, said.

It will initially contain 25 clinically actionable genes, several of which are protected by Myriad's intellectual property, that will be analyzed both for single-base changes and large rearrangements, primarily by next-generation sequencing.

The myRisk Hereditary Cancer panel will have a turnaround time of 14 days or less and a list price between $4,000 and $4,500, said Capone.

The panel currently includes eight genes proprietary to Myriad – BRCA1, BRCA2, BART, RAD51C, PALB2, PTEN, MYH, and P16. The company plans to add other such genes, including MITF and ELAC2, in the future.

By mid-2015, the new test will replace Myriad's BRACAnalysis, Colaris, Colaris AP, Melaris, and Panexia tests, which will be discontinued.

BRACAnalysis currently makes up the majority of Myriad's revenues. During the second quarter, the company recorded $115.4 million in revenues from this test and $16.9 million from the BRACAnalysis Large Rearrangement Test. Its total revenues for the quarter were $156.5 million, up 21 percent year over year.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.